

Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

October 30,2023

To, The Corporate Relations Department The BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001 **Ref:- Scrip Code:- 500459**  To, The Listing Department The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 **Ref:- Scrip Code:- PGHH** 

Dear Sir / Madam,

### Sub:- Unaudited Financial Results for the quarter ended September 30, 2023

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 4.25 pm and ended at 4:53 pm), the Unaudited Financial Results for the quarter ended September 30, 2023 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2023;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2023 furnished by Statutory Auditors of the Company.

Kindly take the same on record. Thanking you.

For Procter & Gamble Hygiene and Health Care Limited

Flavia Machado Senior Legal Manager- Legal and Secretarial



Procter & Gamble Hygiene and Health Care Limited CIN : L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 (91 - 22) 2826 6000 phone (91 – 22) 2826 7337 fax Website: in.pg.com

	STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE Q	UARTER ENDED 30th SE	PTEMBER 2023		(₹ in Lakhs)
		(1)	(2)	(3)	(4)
			Preceding	Corresponding	Previous
	Particulars	Three Months	Three Months	Three Months	Year
		Ended	Ended	Ended	Ended
		30th Sept 2023	30th June 2023	30th Sept 2022	30th June 2023
			(Audited)		
		(Unaudited)	Refer note 4	(Unaudited)	(Audited)
1 Income					
Sale of products		1 13 506	84 874	1 04 092	3 90 521
		329	379	397	
Other operating		1 13 835	85 253	1 04 489	1 269 3 91 790
2 Revenue from o 3 Other income	perations				
3 Other income	T-(-) (	1 577	1 010	673	4 058
	Total income (2+3)	1 15 412	86 263	1 05 162	3 95 848
4 Expenses					
a) Cost of raw and	packing materials consumed	21 652	19 990	26 630	84 755
b) Purchases of sto	ck-in-trade (Traded goods)	22 285	19 309	21 142	82 401
c) Changes in inver	tories of finished goods, work-in-progress and stock-in-trade	574	( 3 321)	( 4 441)	( 853)
d) Employee benefi	ts expense	6 372	4 807	5 126	20 579
e) Finance costs		189	300	95	1 138
	amortization expense	1 430	1 541	1 396	5 836
,	es promotion expenses	15 347	5 354	15 569	42 652
h) Other expenses		19 116	17 625	19 065	75 393
	Total expenses	86 965	65 605	84 582	3 11 901
5 Profit before tax	: (2+3-4)	28 447	20 658	20 580	83 947
6 Tax expense					
a) Current tax		7 533	5 448	5 415	23 052
<li>b) Deferred tax</li>		( 155)	86	( 276)	( 1 208)
<li>c) Prior year tax ad</li>	ustments (Refer note 2)				(5711)
		7 378	5 534	5 139	16 133
7 Profit for the pe	riod (5-6)	21 069	15 124	15 441	67 814
8 Other comprehe	ensive income				
Items that will no	t be reclassified to profit or loss:				
Remeasurement	of the defined benefit plans	( 250)	( 989)	182	( 999)
Income tax effec	t on above	63	248	(46)	251
Total other com	prehensive income for the period	( 187)	( 741)	136	( 748)
9 Total comprehe	nsive income for the period (7+8)	20 882	14 383	15 577	67 066
10 Paid-up equity sl	nare capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246
11 Other Equity					91 357
12 Earnings per Sh	are (Face value of ₹ 10 per equity share) (not annualised) :				
a) Basic		64.91	46.59	47.57	208.91
b) Diluted		64.91	46.59	47.57	208.91
	otes to the financial results	1			

Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 30, 2023

and have been subjected to a limited review by the Statut Committee and approved by the Statut Committee and

4 The figures for the preceding three months ended June 30, 2023 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2023 and the year to date figures upto the third quarter of that financial year.

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited

Vaidyanathan Digitally signed by Vaidyanathan Viswanathan Lalgudi Lalgudi 16:41:24 + 05'30'

LV Vaidyanathan Managing Director

Place: Mumbai Date: October 30, 2023



Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai - 400099 Tel: (91-22) 2826 6000 Fax: (91-22) 2826 7337 Website: in.pg.com

## Procter & Gamble Hygiene and Health Care Ltd. announces first quarter results

Sales up 9%, and PAT up 36% for the quarter ended September 30, 2023

Mumbai, October 30, 2023: Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended September 30, 2023. During the quarter, the Company delivered a strong growth with sales of ₹1138 crore, up 9% versus year ago driven by a superior retail execution and integrated growth strategy. Profit After Tax (PAT) for the quarter was ₹211 crore, up 36% versus year ago led by acceleration of volume growth coupled with product price-mix and productivity.

### LV Vaidyanathan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd.

shared, "We delivered a strong top and bottom-line growth in the quarter, by executingour integrated strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption, and an agile and accountable organization. Our team's execution of these strategies has enabled us to build momentum in the first quarter, and we are confident that these strategies will help us deliver balanced growth and value creation."

The Company's business continues to grow behind a strong product portfolio, superior consumer communication and a continuous stream of product innovations aimed at delighting consumers, like Whisper Hygiene Comfort, Whisper Choice Nights, Vicks ZzzQuil-World's #1 Sleep Supplement, Vicks Roll-On Inhaler and Vicks Xtra Strong. Whisper also continues to raise awareness about menstrual hygiene education through 'Whisper Menstrual Health & Hygiene Program'.

#### About Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's leading FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No.1 Health Care brand and Old Spice. The company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through superior value propositions. Please visit in.pg.com for the latest news.

#### For details contact: Madison Public Relations:

Malika Bhavnani +91 9820496099; malika.bhavnani@madisonpr.in

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

#### *REVIEW REPORT TO THE BOARD OF DIRECTORS PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED*

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of **PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED** ("the Company") for the quarter ended September 30, 2023, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (initialled by us for identification). This Statement which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on October 30, 2023, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Attention is drawn on the fact that the figures for the three months ended June 30, 2023 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the end of the third quarter of the previous financial year. The figures up to the end of the third quarter of the previous financial year had only been reviewed and not subjected to audit.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALYANIWALLA & MISTRY LLP CHARTERED ACCOUNTANTS Firm Regn. No.: 104607W / W100166

ROSHNI RAYOMAND MARFATIA

Roshni R Marfatia PARTNER M. No.: 106548 UDIN: 23106548BGUWEF1810

Mumbai: October 30, 2023.

Highly Restricted



Procter & Gamble Hygiene and Heatth Care Limited CIN : L24230MH1964PLC012971 Registered Office: P&& Claza Cardinal Gracias Road, Charkala Andheri (E), Mumbai 400 099 (91 - 22) 2826 6000 phone (91 - 22) 2826 7337 fax Website: In.pg.com

Particulars         (1)         (2) <t< th=""><th>ars Three M Ende 300h Sep 300h</th><th>(1)</th><th>(2)</th><th>(3)</th><th>101</th></t<>	ars Three M Ende 300h Sep 300h	(1)	(2)	(3)	101	
Incention         Three Months Three Months Ended         Three Months Three Months Ended         Corresponding Ended         Correspond	lars Three M Ende Ende 30th Sep 30th Se		Ì	2	(t)	
Interm         Three Months	ars Three M Ende Ende 300h Separation (Unaud P 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Preceding	Corresponding	Previous	
Ended         Ended <th< td=""><td>cin-progress and stock-in-trade (Unaud cin-progress and stock-in-trade 1 </td><td>Three Months</td><td>Three Months</td><td>Three Months</td><td>Year</td></th<>	cin-progress and stock-in-trade (Unaud cin-progress and stock-in-trade 1 	Three Months	Three Months	Three Months	Year	
30th Setr 2023         30th Se	30th Sep     30th Sep       naud     0       naud     1       ne     1	Ended	Ended	Ended	Ended	
Imanufaction         Mutaneo         (Unaudited)	(Unaud cin-progress and stock-in-trade cin-progress and cin-progress and c	30th Sept 2023	30th June 2023	30th Sept 2022	30th June 2023	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	tin-progress and stock-in-trade	(Unaudited)	(Audited) Refer note 4	(Unaudited)	(Audited)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	chi-progress and stock-in-trade					
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	the progress and stock-in-trade the (2+3) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
329         379         1 $(2+3)$ $1577$ $86 263$ $1$ $1577$ $1652$ $19 980$ $1$ $1577$ $86 263$ $1$ $1010$ $1577$ $86 263$ $1$ $1010$ $1577$ $86 263$ $1010$ $321$ $113 372$ $574$ $321$ $(126)$ $574$ $5347$ $534$ $321$ $1130$ $1130$ $1541$ $1565$ $1130$ $15347$ $534$ $1566$ $11430$ $15347$ $534$ $1565$ $11430$ $15347$ $1565$ $1524$ $11430$ $15347$ $1565$ $1524$ $11616$ $17553$ $544$ $2166$ $11616$ $15724$ $15124$ $1639$ $1740$ $16160$ $16116$ $1234$ $1740$ $1233$ $246$ $216$ $1740$ $1234$ $1234$ $124$	cin-progress and stock-in-trade	1 13 506	84 874	1 04 092	3 90 521	
113         113         113         85.53         1           ome (2+3)         115/7         15/7         86.253         1           in-progress and stock-in-trade         574         (3321)         (1010           cin-progress and stock-in-trade         574         (3321)         (1541)           cin-progress and stock-in-trade         6372         4807         (1541)           cin-progress and stock-in-trade         28.47         20.658         (155)           cin-progress         7.533         5.448         (155)         (155)           cin-progress         (155)         (155)         (155)         (152)           cin-progress         (155)         (155)         (1512)         (1512)           cin-progress         (155)         (155)         (1512)         (1512)           cin-progress         (155)         (155)         (1512)         (1611)           cin-progress         (153)         (248)         (248)         <	ome (2+3)     1       ome (2+3)     1       -in-progress and stock-in-trade     1       cipenses     1       s:     1       s:     1       per equity share)     1       oquity share) (not amualised) :     1	329	379	397	1 269	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	ome (2+3) 1 -in-progress and stock-in-trade penses s: s: s: (7+8) per equity share) per equity share) (not amualised) :	1 13 835	85 253	1 04 489	3 91 790	
ome (2+3)         115 412         86 263         1           cin-progress and stock-in-trade $574$ (19 30)         (19 30)           cin-progress and stock-in-trade $574$ (3 321)         ( $6772$ $732$ $990$ $300$ ( $7372$ $732$ $321$ (         (         ( $6772$ $6772$ $67347$ ( $3321$ ( $6772$ $6965$ $665$ $300$ (         ( $67347$ $17625$ (         ( $67347$ $17625$ $6665$ $6665$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66565$ $66765$ $6748$ $674$	ome (2+3) 1 cin-progress and stock-in-trade (penses (penses) 1 (penses) 1	1 577	1 010	673	4 058	
$ \begin{array}{c} 21.652 \\ \text{in-Progress and stock-in-trade} \\ 574 \\ 6.72 \\ 1.3 \\ 2.2 \\ 2.2 \\ 3.27 \\ 1.3 \\ 3.21 \\ 3.21 \\ 3.00 \\ 1.5 \\ 3.00 \\ 1.5 \\ 3.00 \\ 1.5 \\ 3.00 \\ 1.5 \\ 3.00 \\ 1.5 \\ 1.7 \\ 2.0 \\ 6.5 \\ 6.5 \\ 6.5 \\ 6.5 \\ 6.5 \\ 1.5 $	-in-progress and stock-in-trade cpenses conditional stock-in-trade conditional stock in-trade conditi	1 15 412	86 263	1 05 162	3 95 848	
21652     19 990 $574$ 321 $574$ 321 $672$ 300 $189$ 300 $1430$ $1837$ $189$ 300 $1430$ $1541$ $1430$ $1541$ $1430$ $1541$ $1430$ $1541$ $1430$ $1541$ $15347$ $26665$ $1916$ $17625$ $1916$ $17625$ $66965$ $6665$ $7333$ $5448$ $7533$ $5448$ $7533$ $5634$ $778$ $5534$ $663$ $15124$ $778$ $21069$ $6191$ $15124$ $778$ $21069$ $778$ $21069$ $778$ $216$ $746$ $3246$ $746$ $3246$ $746$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $3246$ $748$ $748$ $748$ <	-in-progress and stock-in-trade cpenses					
	-in-progress and stock-in-trade <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b> <b>cpenses</b>	010	000 01	000 00	115 10	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	cin-progress and stock-in-trade (penses (7+8)) eried (7+8) per equity share) (not amualised) :	21 652	19 990	26 630	cc/ 48	
$ \begin{array}{c} \mbox{:in-progress and stock-in-trade} & 574 & (3 321) & ( \\ 3372 & 3321 & ( 3 321) & ( 1 4 30 & 1541 & 1 3 0 & 1541 & 1 1 6 & 1 7 6 25 & 3 0 & 1 6 1 & 1 7 6 & 2 0 & 6 & 8 & 6 & 6 & 6 & 6 & 6 & 6 & 6 & 6$	-in-progress and stock-in-trade <b>cpenses</b> s: (7+8) per equity share) (not amualsed) :	22 285	19 309	21 142	82 401	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	cpenses	574	(3321)	(4441)	(853)	
1189     300       15347     1541       15347     5354       15347     5354       15347     5365       1541     17625       1541     17625       1553     5448       7533     5448       7533     5448       7533     5448       7533     5448       7533     5448       7533     5448       7533     5448       7533     5448       7378     5534       7378     5534       7378     5534       738     548       63     15124       746     15124       738     546       746     3246       748     3246       748     3246       748     3246       748     3246       64.91     46.59       64.91     46.59       64.91     64.91       64.91     64.91	cpenses constant s: (7+8) per equity share) oquity share) (not amuaised) :	6 372	4 807	5 126	20 579	
1430     1541       1916     1563       1916     17625       1916     17625       2847     2068       7533     5448       7533     5448       7338     534       7378     534       6199     15124       533     5448       7378     534       63     534       63     15124       7378     534       7378     534       63     15124       7378     548       63     15124       7378     534       7378     548       63     21069       746     3246       7433     3246       7433     3246       7459     3246       9qufty share)     3246       9qufty share)     3246       64.91     46.59       64.91     46.59	cpenses cpenses contract of the contract of th	189	300	95	1 138	
	cpenses	1 430	1 541	1 396	5 836	
19 116         17 625           cpenses         86 965         65 605           20 457         20 658           7 533         5 448           7 533         5 448           7 533         5 448           7 533         5 448           7 533         5 448           7 533         5 448           7 533         5 448           7 533         5 448           7 378         5 534           63         21 069         15 124           8:         7 378         5 534           8:         7 378         5 534           8:         7 378         5 534           9:         63         248           8:         15 124         248           8:         16 3 246         3 246           9:         23 245         3 246           9:         14 333         3 246           9:         16 4.91         46.59           64.91         64.91         46.59	cpenses contraction in the contraction of the contr	15 347	5 354	15 569	42 652	
cpenses         86 965         65 605         65 605           7 533         5 448         7 533         5 448           7 533         5 448         86         86           7 533         5 448         86         86           7 533         5 448         86         86           7 533         5 448         86         86           7 378         5 5 34         21         86           7 378         5 5 34         248         248           eriod         (187)         (741)         (741)           (748)         3 246         3 246         3 246           squity share)         (not annualised) :         64.91         46.59           64.91         64.91         46.59         64.91	cpenses cpenses compared to the second compared to the second compared to the second compared	19116	17 625	19 065	75 393	
28 447     20 658       7 533     5 448       7 533     5 448       ( 155)     86       7 378     5 534       7 378     5 534       21 069     15 124       63     15 124       63     248       63     248       7 378     5 34       7 378     5 34       7 378     5 34       7 378     5 34       7 310     248       63     248       7 410     14 383       7 410     14 383       7 90 882     14 383       9 outly share)     3 246       9 outly share)     3 246       9 outly share)     64.91       64.91     46.59	s: eriod (7+8) per equity share) equity share) (not amualsed) :	86 965	65 605	84 582	3 11 901	
28 47         20 658           7 533         5 448           7 533         5 448                    7 378         5 5 34            7 378         5 5 34            7 378         5 5 34            7 378         5 5 34            7 378         5 5 34            7 3 78         5 5 34            7 3 78         5 5 34            6 3 0         2 48              2 48              2 48	s: eriod (748) per equity share) squity share) (not amualised) :					
7         533         5         448           (         155)         66         65<	is: eriod (748) per equity share) squity share) (not amuaised) :	28 447	20 658	20 580	83 947	
7 533     5 448       7 378     5 534	is: eriod (7+8) per equity share) squity share) (not amualsed) :					
(155)         86           7378         534           71069         15124           534         21069           63         15124           63         248           63         248           778         534           7178         248           7793         248           7793         248           7793         246           741         1733           7793         3246           741         14333           64.91         46.59           64.91         46.59           64.91         46.59	is: eriod (7+6) per equity share) equity share) (not annualised) :	7 533	5 448	5415	23 052	
as: ( 7 378 5 5 34 5 21 069 15 124 15 21 069 15 124 15 21 069 15 124 15 ( 250) ( 989) ( 63 ( 187) ( 741) 15 ( 741) 246 31 746 33 45 per equity share) (not annualised) : 64.91 46.59 41 64.91 46.59 41	is: eriod (748) per equity share) squity share) (not amualised) :	( 155)	86	( 276)	( 1 208)	
7         7         7         5         5         5         5         5         3         5         3         5         3         5         3         5         3         5         3         5         3         3         3         3         3         3         3         4	is: eriod (7+8) per equity share) squity share) (not annualised) :		1	1	( 5711)	
21 069         15 124         15           is:         (250)         (989)         (111)           eriod         (63)         248         (151)           (74)         (741)         (741)         (151)           (748)         238         14333         15           per equity share)         3246         3246         346           aquity share)         (not ammalised):         64.91         46.59         41	is: eriod (7+6) per equity share) squity share) (not annualsed) :	7 378	5 534	5 139	16 133	
is: eriod (748) (748) (741) (741) (741) (741) (741) (741) (741) (741) (741) (741) (741) (741) (741) (741) (763	s: eriod (7+8) per equity share) squity share) (not annualised) :	21 069	15124	15 441	67 814	
s: ( 250) ( 989) ( 63 ( 741) ( 741) ( 741) ( 787) ( 741)	s: eriod (748) per equity share) squity share) (not annualised) :					
(250)         (989)         (174)         (187)         (187)         (183)         (155) <th< td=""><td>eriod (7+6) per equity share) squity share) (not amualsed) :</td><td></td><td></td><td></td><td></td></th<>	eriod (7+6) per equity share) squity share) (not amualsed) :					
eriod         63         248         (           (748)         (         187)         (         741)         15           (748)         20.882         14.383         15         3         15           per equity share)         3.246         3.246         3         3         3           squity share)         3.246         3.246         3         3         3           squity share)         (not annualsed)         5.46         46.59         41	eriod (7+6) per equity share) squity share) (not annualsed) :	( 250)	( 686)	182	(666)	
eriod (748) (741) (741) (741) (748) (748) (749) (749) (749) (749) (749) (741)	eriod (748) 208 (748) 208 (748) 208 (748) 208 (748) 208 (748) 208 per equity share) (not annualsed) : 64 64	63	248	( 46)	251	
7.400         20.882         14.333         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.433         7.46         7.433         7.46 <th 7<="" td=""><td>7.450 (7.45) per equity share) squity share) (not annualsed) :</td><td>( 187)</td><td>1 741)</td><td>136</td><td>1 748/</td></th>	<td>7.450 (7.45) per equity share) squity share) (not annualsed) :</td> <td>( 187)</td> <td>1 741)</td> <td>136</td> <td>1 748/</td>	7.450 (7.45) per equity share) squity share) (not annualsed) :	( 187)	1 741)	136	1 748/
oper equity share) 3 246 3 246 3 246 3 246 3 246 3 246 3 246 3 246 3 246 3 246 6 4.91 46.59 64.91 46.59 64.91 46.59	(170) per equity share) squity share) (not annualised) :	20 88 0	1121	46 677	990 29	
per equity share) (not annualised) : 5.246 5.59 64.91 46.59 64.91 46.59	per equity share) (not annualised) : squity share) (not annualised) :	200 02	14 303	110 01	00 /0	
squity share) (not annualised) : 64.91 46.59 64.91 46.59 64.91	əquity share) (not annualised) :	3 240	3 240	3 240	3 240	
squry snare) (not ambailsed) : 64.91 46.59 64.91 46.59 64.91 46.59	squity snare) (not annualsed) :				100 16	
64.91 46.59 64.91 46.59			01	[		
64.91 49.59		04.91	40.59	10.14	208.91	
		04.91	40.04	10.14	200.31	
		-				

The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 30, 2023 and have been subjected to a lined review by the Staunory Auditors of the Company.
 During the pervious year ended June 2023, the Company reversed tax provisions amounting to Rs. 5,844 lakhs in respect of past Income Tax Litigations pertaining to certain years, beach on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
 The Gurase of the proceeding three months ended June 30, 2023 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2023 and the year to date figures upto the third quarter of that financial year.

Place: Mumbai Date: October 30, 2023

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited Vaidyanathan Digitally signed by Viswanathan Viswanthan Lagud Lalgudi 16:41:34 + 05'30

LV Vaidyanathan Managing Director

 Parson d. postalić ode–40 91–14 dvarad sr.g. stroet –14 a. Marsbai, Marsbail Mahu 31. Near Electric House, 01